The FDA decision on the expanded use of Linzess for the treatment of functional constipation in children and adolescents 6 to 17 years of age is expected on June 14, 2023.Linzess is already approved in adults for treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).The drug is developed and marketed by Ironwood Pharmaceuticals and AbbVie (ABBV) in the United States.Ironwood’s share of net profits from the sales of Linzess in the U.S. was $398.8 million for full year 2022 compared to $400.4 million in the prior year.IRWD closed Friday’s (May 26, 2023) trading at $10.81, up 0.75%.